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Vascular endothelial growth factor-A is widely regarded as the principal stimulator of angiogenesis required for tumour growth. VEGF
is generated as multiple isoforms of two families, the pro-angiogenic family generated by proximal splice site selection in the terminal
exon, termed VEGFxxx, and the anti-angiogenic family formed by distal splice site selection in the terminal exon, termed VEGFxxxb,
where xxx is the amino acid number. The most studied isoforms, VEGF165 and VEGF165b have been shown to be present in tumour
and normal tissues respectively. VEGF165b has been shown to inhibit VEGF- and hypoxia-induced angiogenesis, and VEGF-induced
cell migration and proliferation in vitro. Here we show that overexpression of VEGF165b by tumour cells inhibits the growth of
prostate carcinoma, Ewing’s sarcoma and renal cell carcinoma in xenografted mouse tumour models. Moreover, VEGF165b
overexpression inhibited tumour cell-mediated migration and proliferation of endothelial cells. These data show that overexpression
of VEGF165b can inhibit growth of multiple tumour types in vivo indicating that VEGF165b has potential as an anti-angiogenic, anti-
tumour strategy in a number of different tumour types, either by control of VEGF165b expression by regulation of splicing,
overexpression of VEGF165b, or therapeutic delivery of VEGF165b to tumours.
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Vascular endothelial growth factor (VEGF-A) is the principal
angiogenic promoter in most, if not all, cancers acting primarily on
endothelial cells through its cognate receptors VEGF-R1 and
VEGF-R2. VEGF is upregulated by hypoxia (Shweiki et al, 1992),
and by overexpression of oncogenes such as mutant ras (Rak et al,
1995) and c-myc (Mezquita et al, 2005) in tumours, and stimulates
the migration of endothelial cells, sprouting of blood vessels, and
generation of new vessels from existing vasculature in tumours
(reviewed in Ferrara, 2004). The resulting sustained blood flow,
oxygen supply and waste removal enables more rapid growth of
the tumour. Anti-VEGF therapy is now an additional therapeutic
strategy to surgery, chemotherapy and radiotherapy, and recent
trials of antibodies to VEGF as adjuvant therapy have shown
significant clinical benefit in colorectal cancer (Hurwitz et al,
2004), renal carcinoma, non small cell lung, ovarian and other
cancers.
Vascular endothelial growth factor is generated as multiple
isoforms by alternative splicing of mRNA from 8 exons (Houck
et al, 1991). Conventional VEGF isoforms are pro-angiogenic, pro-
permeability vasodilators. These isoforms contain exons 1–5 and
8a, with a variable contribution from exons 6a, 6b, 7a, and 7b,
resulting in a family of peptides identified numerically by their
amino-acid content, each with different heparin-binding proper-
ties (Houck et al, 1991). These are generically identified as
VEGFxxx, where xxx refers to the number of amino acids. In 2002
(Bates et al, 2002) and 2004 (Woolard et al, 2004) we identified a
sister family of isoforms of identical lengths and exon structure
apart from the C-terminal exon in which distal splicing results in
an alternate open-reading frame of six amino acids (exon 8b rather
than 8a, SLTRKD vs CDKPRR) – generically referred to as
VEGFxxxb (e.g. VEGF165b, VEGF121b (Perrin et al, 2005), VEGF189b
(Miller-Kasprzak and Jagodzinski, 2008)). These isoforms are
antiangiogenic and downregulated in renal tumours and metastatic
melanoma (Bates et al, 2002; Pritchard-Jones et al, 2007). This
antiangiogenic activity, generated by receptor binding but only
weak receptor activation (Cebe Suarez et al, 2006) and inhibition
of downstream VEGF-R2 signalling, has led to the hypothesis that
VEGF165b, or manipulation of C-terminal VEGF splicing to
enhance more distal splicing, may be useful therapeutic tools in
cancer.
We have previously shown that VEGF165b is present in a range
of normal tissues (Bates et al, 2002; Woolard et al, 2004) and there
is a downregulation of the antiangiogenic VEGF165b protein in
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smalignant prostate cancer (Woolard et al, 2004) and metastatic
melanoma (Pritchard-Jones et al, 2007) and mRNA in renal
carcinoma (Bates et al, 2002). We also showed that VEGF165
expressing tumours grew faster than VEGF165b expressing
tumours, suggesting that VEGF165b was not angiogenic. Moreover,
we showed that tumours in which VEGF165b expressing cells were
mixed with VEGF165 expressing cells grew more slowly than cells
only expressing VEGF165 (but more quickly than cells expressing
VEGF165b alone). This latter finding rules out a possibility that
VEGF165b could be angiogenic in the presence of VEGF165.
However, neither that, nor any other study, has shown whether
VEGF165b can inhibit tumour growth, whether it can inhibit
VEGF165-mediated tumour growth, or whether it can do so by
inhibiting angiogenesis.
In this study, we have examined the effect of VEGF165b
overexpression on tumour growth, and VEGF165-mediated angio-
genesis of prostate and renal cell carcinoma and on growth of
Ewing’s sarcoma cell and metastatic melanoma in xenografted
mouse models.
MATERIALS AND METHODS
Human tissue and RT–PCR of human TURP chips
Frozen prostate chips were obtained from patients undergoing
transurethral resection of the prostate (TURP) for lower urinary
tract symptoms with benign prostatic hyperplasia and advanced
prostate cancer (stage T3 Nx M0-1; UICC2002). The use of tissue
was approved by the NBHST Ethical Committee.
Fifty to 100mg of 26 TURP tissue (nine malignant, 17 benign
prostatic hypertrophy) was homogenised in Trizol reagent (Life
Technologies Inc., Rockville, MD, USA) and mRNA was extracted
by using the method of (Chomczynski and Sacchi, 1987). Eight
microliters of RNA were treated with RNase free DNase (Promega,
Madison, WI, USA) according to the manufacturer’s guidelines to
prevent genomic DNA contamination and mRNA was reverse
transcribed using Moloney murine leukaemia virus reverse
transcriptase and poly-d(T). cDNA was then amplified using
intron spanning primers that detect VEGF165b only, even in the
presence of 1000 fold greater concentration of VEGF165 mRNA
(Bates et al, 2002). The cDNA was amplified using 1mM intron-
spanning primers designed to detect VEGFxxxb (Bates et al, 2002)
(Exon 4, 50-GAGATGAGCTTCCTACAGCAC-30 and (Exon8b/7, 50-TT
AAGCTTTCAGTCTTTCCTGGTGAGAGATCTGCA-30) or VEGFxxx
with exon 8a (50-CACCGCCTCGGCTTGTCACAT-30), together with
1.2mM MgCl2, 200mM dNTPs, and 1 unit of Taq DNA polymerase
(Abgene), cycled 35 times, at 941C for 30s, 631C for 30s and 721C
for 60s. b2-microglobulin was used as control amplification (b2
forward primer 50-GCATCATGGAGGTTTGAAGATG-30, b2 reverse
50-TAAGTTGCCAGCCCTCCTAGAG-30)a t5 5 1C annealing tem-
perature leading to a 220bp product. Full-length VEGF165bo r
VEGF165 in pcDNA3 vector were used as positive and negative
controls. PCR products were run on 3% agarose gels. PCR bands
were excised and extracted using Qiaex (Qiagen, Crawley, UK),
cloned using a TOPO TA Cloning
s Kit (Invitrogen, Paisley, UK)
and confirmed by sequencing.
Establishment of overexpressing tumour cells
All media and supplements were from Gibco/Invitrogen if not
otherwise stated. PC3 cells were kindly donated by Professor J
Masters from UCH, University of London. Ewing’s sarcoma cell
line, TC71, renal cell carcinoma cell line, CAKI, prostate cell line,
PC3, and melanoma cell line, Mel57, were grown in Eagle’s
modified essential medium supplemented with 10% fetal calf
serum (FCS), 2mML -glutamine, 1mM sodium pyruvate, 1%
non-essential amino acids, NEAA, 2% minimum essential medium
vitamin solution, minimum essential media (Sigma Aldrich,
Dorset, UK) supplemented with 10% FCS, 1% L-glutamine, 1%
penicillin/streptomycin, 1% NEAA or McCoy’s 5A medium
supplemented with 10% FCS and Ham F-12 supplemented with
10% FCS, 1% penicillin/streptomycin, 1.5gl
 1 sodium bicarbonate
(Sigma Aldrich), respectively.
For transfection, 90% confluent cells in 6-well plates were
transfected with 0.5mg of plasmid DNA (pcDNA empty vector,
pcDNA-VEGF165, pcDNA-VEGF165b or equal amounts of VEGF165
and VEGF165b plasmids) using Lipofectamine 2000 (Invitrogen,
Paisley, UK) according to manufacturers protocols and Optimem
media. Cells were selected with 375mgml
 1 of geneticin and
maintained at 125mgml
 1. Transfected cells were analysed by an
in-house developed VEGF165b-specific enzyme-linked immuno-
sorbent assay (ELISA) (Perrin et al, 2005) or a commercial
panVEGF ELISA (Duoset, R&D Systems), that detects all isoforms
of VEGF-A, to validate expression levels in selected cells. ELISA
was performed either according to manufacturers instructions or
as previously described (Woolard et al, 2004). Conditioned media
from 200000 cells was collected and was analysed by ELISA after
48h incubation. Mel57 cells were transfected with plasmid
pIRESneo containing the VEGF165 or VEGF165b cDNA essentially
as described before (Kusters et al, 2007).
Migration of cells with conditioned media
Cultured supernatants from TC71, empty vector transfected TC71
or TC71/VEGF165b cells were collected. Transwells (Costar,
Cambridge, MA, USA) were pretreated with serum-free
medium at 371C for 1h before seeding with human dermal
microvascular endothelial cells, (HMVECs)at 1 10
5 per well in
100ml endothelial basal media (Cambrex, Baltimore, MD, USA)
with 0.1% fetal bovine serum. These cells are commercially
available cells generated from human foreskin tissue. The
transwells were then inserted into 24-well plates containing
600ml of conditioned medium and incubated at 371C for 6h to
allow HMVEC cells to migrate. Cells on the upper side of the filter
were removed with cotton swabs. Migrated cells on the lower side
of the filter were fixed and stained with haematoxylin and eosin.
The number of migrated cells was counted under a binocular
microscope.
[
3H]-thymidine incorporation of cells with conditioned
media
Human dermal microvascular endothelial cells (3 10
3) were
seeded into 96-well cell culture plates and allowed to adhere for 5h
before the addition of conditioned medium from TC71 cells, empty
vector transfected TC71 cells or TC71/VEGF165b cells. Triplicate
wells were used for each group. The cultures were labelled with
0.2mCi per well of [
3H] thymidine (ICN Biomedicals Inc.,
Radiochemicals Division, Irvine, CA, USA) during the last 24h
of a 48h incubation. At the end of incubation, the cells were
washed two times with HBSS, and 0.1ml of 0.1N KOH was added
to lyse the adherent cells. The radioactive incorporation was
determined using a plate harvester (Brandal Biomedical Research
and Development Lab Inc., Gaithersburg, MD, USA) and Beta Plate
Counter (Wallac 1450 Micro beta Counter, Perkin Elmer Life
Sciences, Turku, Finland).
In vitro growth analysis of cells
For direct counting and proliferation of transfected CAKI cells,
30000 cells per 24 well were seeded out in triplicates. Cells were
maintained in media supplemented with 0.01% or 10% FCS and
were counted after 24 or 48h. The doubling time for each cell
population was calculated using Prism software. The metabolic
rate was analysed by seeding 5000 cells per 96 well in media
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ssupplemented with 0.01% FCS. After 24 or 48h 50ml of metabolic
reagent was added (CellTiter 96
s Aqueous One solution, Promega,
Madison, WI, USA). Cells were incubated for 4h at 371C and
analysed at 490nm.
Animal housing and xenograft model
One million Ewing sarcoma or Mel57, 8 million CAKI, 3 million
PC3 overexpressing cells were injected subcutaneously into the
back of unanaesthetised nude mice in 100ml sterile PBS.
Xenotransplanted tumours were measured by calliper and tumour
volume was calculated according to (length width (lengthþ
width)/2). Mice were culled by cervical dislocation when tumours
reached 16mm in any direction and organs and tumours were
removed and snap-frozen or fixed in 4% PFA followed by paraffin
embedding and 5mm sections were generated and stained with
CD31/PECAM. Slides were boiled for 10min in 0.01 M sodium
citrate boiling, followed by blocking in 5% goat serum for 1h,
overnight incubation with 2.5mgml
 1 anti-mouse PECAM anti-
body (Pierce Endogen) and for 1h in 5mgml
 1 ALEXA Fluor 488
goat anti hamster IgG (Invitrogen, Molecular Probes). Vessels were
counted in six different fields at  20 magnification and verified at
 40 magnification. Nude mice were kept under appropriate
specific pathogen-free housing facilities according to government
guidelines and procedures were carried out according to national
guidelines and regulations.
Statistical analysis
Statistical analysis was performed using Prism. All data are
given as mean±s.e.m. if not otherwise stated. Number of
benign TUR and malignant chips expressing VEGF165b was
compared using Fisher’s exact test. For tumour growth one-way
analysis of variance (ANOVA) followed by Newman–Keuls’
post hoc test (prostate) or two-way ANOVA followed by Bonferroni
post hoc test (renal carcinoma) were used as data allowed. Weight,
blood score, proliferation, cell doubling and metabolic rate were
analysed by one-way ANOVA followed by Newman–Keuls’
multiple comparison post hoc test. Po0.05 was considered
significant.
RESULTS
VEGF165b is downregulated in malignant prostate tumours
compared to benign prostate tissue and reduced tumour
growth in xenograft model
RNA was extracted from human prostate chips from patients
undergoing TURP and expression of VEGF165 and VEGF165b
mRNA was analysed by isoform specific PCR. Expression of
VEGF165b was found in 10 out of 11 benign samples and VEGF165
was also present in 10 out of 11 (see Figure 1A). In malignant
prostate on the other hand, VEGF165b was only found in four out
of nine, whereas the VEGF165 expression was found in eight out of
nine (see Figure 1B).
Human prostate cancer cells, PC3 cells, were transfected with
control, VEGF165b, VEGF165 expression plasmids, or a combina-
tion of the two and injected into nude mice. The tumour volume
was monitored over time and at day 18 the tumour volumes were
significantly different (Po0.05). Figure 1C–F illustrates represen-
tative images of each group. The pro-angiogenic VEGF165
transfected cells produced rapidly growing tumours although not
statistically different from control tumours (P40.5). Conversely
the VEGF165b transfectants resulted in smaller tumours (Po0.05 at
22 days compared with pcDNA3 controls), and those expressing
both isoforms were significantly smaller than those expressing
VEGF165 only (Po0.05 at 18 days).
Benign prostate chips
A
Malignant prostate chips
B
G
VEGFxxxb
VEGFxxx
VEGF165b
0
200
400
600
800
1000
1200
0 5 10 15 20
Days after implantation
Control
VEGF165
VEGF165b
VEGF165+165b
+
∗
C D
F E
Control VEGF165
VEGF165b VEGF165+165b
VEGF165 H2O
Tumour growth of PC3 cells
T
u
m
o
u
r
 
v
o
l
u
m
e
 
(
m
m
3
)
Figure 1 The antiangiogenic VEGF165b is downregulated in human malignant prostate tumour and reduces prostate tumour growth. Anonymous
examples of VEGFxxx and VEGFxxxb mRNA expression in TURP chips from benign prostate hypertrophy (A) and malignant prostate cancer (B). (A)R T–
PCR of mRNA extracted from benign prostate chips using primers to detect VEGFxxxb and VEGFxxx. Ten out of 11 benign samples showed expression of
VEGFxxxb. All but one sample also showed VEGF165 expression. (B) RT–PCR of RNA extracted from malignant prostate chips. Only four of the nine
malignant samples showed expression of VEGF165b and eight out of nine malignant samples showed VEGF165 expression. b-microglobulin expression was
seen in all the malignant tissues (data not shown). (C–F) Images of tumour-bearing mice. Tumours from PC3 cells overexpressing empty pcDNA3 vector
(C), VEGF165 (D), VEGF165b( E) and cotransfection with VEGF165 and VEGF165b( F). Scale bar¼10mm. (G) VEGF165b reduced prostate tumour growth in
a xenograft mouse model. Three million PC3 cells were injected and VEGF165b overexpression reduced control and VEGF165-mediated tumour growth at
day 18 (Po0.05 Kruskal–Wallis, *control vs VEGF165b Po0.05,
þVEGF165 vs VEGF165b Po0.05).
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sVEGF165b overexpression reduces renal cell carcinoma
growth
Renal carcinoma (CAKI) cells, transfected with the different VEGF
isoforms were analysed for VEGF expression. VEGF165b was
undetectable in empty vector and VEGF165-transfected cells and
VEGF165b expression was readily detectable in the VEGF165b- or
cotransfected cells (Table 1). The endogenous levels of VEGF165
were high in CAKI cells and transfection of VEGF165 increased the
total levels (Table 1).
Eight million transfected CAKI cells were injected into nude
mice and monitored over time. Injection of control transfected
cells resulted in solid, bloody tumours after 29 days (see
Figure 2A), and VEGF165-expressing tumours resulted in larger,
bloody tumours after 29 days (see Figure 2B), VEGF165b-
expressing tumours, while they did grow (see Figure 2C) were
smaller, and less bloody. Cells expressing both isoforms also
resulted in small, relatively blood-free tumours that were not
different from the VEGF165b-expressing tumours (see Figure 2D).
Figure 2E shows that VEGF165b-expressing tumours grew sig-
nificantly slower than VEGF165-expressing tumours (overall
Po0.001, VEGF165 vs VEGF165b Po0.05 at day 27, VEGF165 vs
both Po0.05 day 24 and Po0.001 day 27). No significant
difference was found between tumours formed from cells
expressing VEGF165 and control or between those expressing
VEGF165b and both VEGF isoforms.
Upon excision of the tumours, they were weighed and scored
blindly for blood content. VEGF165-expressing tumours were
significantly larger (see Figure 2F) than control and VEGF165b-
expressing tumours, which also resulted in a significant reduction
of tumour volume (Po0.05 VEGF165 vs both isoforms or
VEGF165b). There was a non-significant reduction in tumour
volume for VEGF165b-expressing tumours compared with control
transfected. Macroscopically the tumours differed with more blood
in VEGF165-expressing tumours compared to any other of the
groups (Po0.01, VEGF165 vs either of the other groups, Figure 2G).
Similar data was observed with a smaller initial tumour cell
injection (2 10
6 cells, data not shown).
The growth rates of the transfected CAKI cells were analysed.
There was no difference in the proliferation as measured by direct
counting of cells (see Figure 3A and B) or analysis of metabolic
rate (see Figure 3C). Both experiments were performed in the
presence of serum with the same results (data not shown).
These results indicate that VEGF165b overexpression reduced
tumour growth in renal cell carcinoma cells grown in mice even in
the presence of VEGF165. The tumour inhibition by VEGF165b
appears not to be through reduction in tumour cell proliferation.
VEGF165b overexpression reduced Ewing’s sarcoma growth
and tumour-conditioned media reduced endothelial cell
proliferation and migration
Injection of TC71 Ewing’s sarcoma cells overexpressing VEGF165b
subcutaneously into the back of nude mice resulted in tumours
that grew significantly slower than control cells over a time period
of 29 days (see Figure 4A). To determine whether VEGF165b
secreted from the tumour cells was active on the cells that go on to
form blood vessels, conditioned media from the Ewing’s sarcoma
cells, TC71 cells, overexpressing VEGF165b was used to study
migration of human microvascular vein endothelial cells, HMVEC.
Fetal calf serum resulted in migration of HMVEC as expected (see
Figure 4B), and conditioned media from control-transfected
tumour cells induced a similar level of migration of HMVEC (see
Figure 4C). VEGF165b overexpressing tumour cells resulted in less
migration compared to tumour-conditioned media or control-
stimulated cells (see Figure 4D).
To determine whether VEGF165b could inhibit growth of
endothelial cells, DNA synthesis in HMVEC was measured.
Table 1 VEGF expression in transfected CAKI cells
Transfection VEGF165b (pgml
 1) Total VEGF (pgml
 1)
pcDNA — 906
VEGF165 — 1020
VEGF165b 1562 1797
VEGF165+165b 975 1424
ELISA performed on conditioned media after 48h from 200000 transfected and
selected CAKI cells.
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Figure 2 VEGF165b inhibits tumour growth in renal cell carcinomas.
Renal cell carcinoma (8 10
6 CAKI) cells, transfected with pcDNA3
vectors expressing empty vector (A) VEGF165 (B), VEGF165b( C)o r
cotransfected with VEGF165 and VEGF165b( D) were injected into the back
of nude mice, n¼6 mice per group, photographs taken at 29 days. Tumour
border outlined by dotted line. Inset shows excised tumours. (E) Tumour
growth curves. (F) Tumour weight at day of culling. (G) Macroscopic
estimation of blood content at day of culling. (*Po0.05 VEGF165b vs
VEGF165,
DPo0.05
DDDPo0.001 VEGF165þ 165b vs VEGF165,
##Po0.01
VEGF165 vs pcDNA).
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3H]-incorporation into HMVECs when added
to control tumour cell-conditioned medium. VEGF165b-condi-
tioned media did not increase DNA synthesis of HMVEC cells and
reduced VEGF165-mediated DNA synthesis (see Figure 4E). How-
ever, VEGF165b did not reduce proliferation below the level of
control-conditioned media, indicating that the inhibition of
proliferation was specific for VEGF165-mediated proliferation.
Rate of tumour growth depends upon the VEGF isoform
expression
The results above suggest that switching expression of VEGF from
VEGF165 to VEGF165b might result in reduced tumour growth
rates. To determine whether this was the case a VEGF-deficient
melanoma cell line (Mel57), which normally grows slowly by co-
option of existing vasculature (Westphal et al, 2000) was
transfected with VEGF165 or VEGF165b, and implanted subcuta-
neously. Figure 5 shows that whereas VEGF165-expressing tumours
rapidly grew, VEGF165b expressing-tumours were very slow
growing, matching that of the previously published co-option
dependent parental cell line, indicating that switching expression
P>0.05
A
50
100
150
200
250
300
C
e
l
l
 
n
u
m
b
e
r
 
(
×
1
0
3
)
0 12 24 36 48
Incubation (h)
Control
VEGF165
VEGF165b
Both
C B
Control VEGF165 VEGF165b VEGF165 VEGF165b Both
P>0.05 P>0.05
0
10
20
30
40
50
D
o
u
b
l
i
n
g
 
t
i
m
e
 
(
h
)
Overexpression vector
Control Both
0
0.25
0.50
0.75
1.00
M
e
t
a
b
o
l
i
c
 
r
a
t
e
 
(
O
D
)
Overexpression vector
Figure 3 Overexpression of VEGF165b does not affect proliferation when overexpressed in renal cell carcinoma cells in vitro.( A, B) Transfected renal cell
carcinoma CAKI cell growth was analysed by direct counting of cells after 24 and 48h in low serum (0.01% FCS). The doubling time was calculated for each
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analysed at 48h in low serum with transfected CAKI cells. No significant difference was observed (P40.05 n¼4, one-way ANOVA).
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tumours 30 days after implantation of 1 10
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one way ANOVA. (B) Human microvascular endothelial cells, HMVECs
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conditioned media from Ewing’s sarcoma cells (C). In contrast VEGF165b
overexpression by these cells reduced migration compared to conditioned
media and 10% serum (D). (E) When HMVECs were incubated in
conditioned media from tumour cells VEGF165 (100ngml
 1) could still
stimulate increased proliferation. Conditioned media from cells over-
expressing VEGF165b inhibited this increase.
VEGF165b inhibits cancer growth in vivo
ES Rennel et al
1254
British Journal of Cancer (2008) 98(7), 1250–1257 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sfrom VEGF165 to VEGF165b by altering splicing may be a useful
therapeutic strategy.
VEGF165b inhibits VEGF165-mediated tumour vessel in-
growth
To examine the mechanism for the reduction of tumour growth in
vivo and the proposed anti-angiogenic effect of VEGF165b, tumour
vessels were visualised by PECAM staining of excised tumour
sections. In the CAKI tumours there was a significant increase in
microvascular density from 7.03±0.86 per high power field in
control (Figure 6A) to 8.37±1.06 in VEGF165-expressing tumours
(Figure 6B). In contrast, there was a significant reduction in MVD
to 2.17±0.65/hpf in VEGF165b-expressing tumours (Po0.01
compared with control Figure 6C), indicating that VEGF165b
inhibited vessel growth in CAKI tumours. This was also
significantly lower than VEGF165 (Po0.001). Furthermore, tu-
mours in which VEGF165b and VEGF165 were coexpressed also had
significantly reduced MVD (2.98±0.56, Figure 6D, Po0.001
compared with VEGF165), indicating that VEGF165b inhibited
VEGF165-mediated blood vessel growth (Figure 6E). Similar results
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Representative images at  10 magnification and  20 (image inset). Quantification of vessel number in CAKI tumours (E) and PC3 (J). Overall Po0.0001
One-way ANOVA Po0.0001 **Po0.01, ***Po0.001 compared to control or VEGF165.
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VEGF165b 0.78±0.78, VEGF165þVEGF165b 0.64±0.64. see Figure
6F–J).
DISCUSSION
VEGF has been generally considered in over 20000 papers since
1990 as a pro-angiogenic tumour-enhancing endothelial-specific
growth factor (Ferrara, 2002) and successful antiangiogenic agents
have been directed at VEGF in cancer and eye disease (Gragoudas
et al, 2004; Hurwitz et al, 2004). In 2002, we identified for the first
time that an alternative splice site in the terminal exon 8 of the
VEGF mRNA could be used to generate an alternative isoform
(Bates et al, 2002), VEGF165b, which we subsequently showed to be
one of a family of VEGF isoforms generated by C-terminal distal
splice site selection, the VEGFxxxb family of isoforms (Perrin et al,
2005). However, while the conventional exon 8a containing
isoforms predominate in the pathological angiogenic phenotype
seen in tumours, proliferative retinopathy, arthritis etc (Ferrara,
2002), the exon 8b containing isoforms, which are anti-angiogenic
in vivo are downregulated in a number of pathologies (Bates et al,
2002; Woolard et al, 2004; Cebe Suarez et al, 2006; Schumacher
et al, 2007). Loss of the C-terminal domain (resulting in VEGF159)
results in a loss of angiogenic activity of the VEGF molecule, but
does not result in inhibition of angiogenesis (Cebe Suarez et al,
2006). The mechanism of action through which VEGFxxxb prevents
tumour growth is not yet fully elucidated. However, it is clear from
previous studies that VEGF165b is able to bind both VEGFR-1
(Cebe Suarez et al, 2006) and VEGFR-2 (Woolard et al, 2004), but
initiates only weak signalling of the receptor to induce tyrosine
phosphorylation (Woolard et al, 2004; Cebe Suarez et al, 2006),
and is unable to induce a behavioural change in large vessel
endothelial cells that mimic that shown by microvascular
endothelial cells in vivo during angiogenesis (Woolard et al,
2004; Cebe Suarez et al, 2006). This study indicates for the first
time that VEGF165b can exert its action by preventing tumour
secreted endothelial growth factors (presumably VEGF165, or other
VEGFxxx isoforms) from acting on microvascular endothelial cells.
Several studies have shown that VEGF expression in the
malignant tissue and/or plasma correlates with aggressive disease
(reviewed in Delongchamps et al, 2006) and VEGF mRNA and
protein are upregulated in prostate carcinoma (Ferrer et al, 1997;
Jackson et al, 1997). Our data indicate that there is a switch in
VEGF expression allowing the pro-angiogenic VEGFxxx isoforms to
dominate within malignant prostate and renal cell carcinoma,
allowing the tumours to develop their own blood supply.
The current findings indicate that VEGF165b may have a
therapeutic role in cancer treatment, by altering splicing of the
VEGF gene to result in over-expression of VEGF165b at the expense
of VEGF165. The latter mechanisms (control of splicing at the
C-terminal end of the VEGF gene), is therefore one of intense
interest, but unfortunately almost nothing has been published
concerning the regulation of splicing of the VEGF gene. The
vascular phenotype in both pathological and physiological
angiogenesis may therefore depend on the balance of VEGF
isoforms. We have speculated then that in addition to malignant
change related to cell turnover/survival (which may also be
determined by splicing (Venables, 2004) a second event occurs in
which splicing control of many factors with pre- and antiangio-
genic splice variants occur to allow the malignant disease to
progress (Ladomery et al, 2006).
To conclude, these findings indicate that VEGF165b is able to
inhibit growth of at least three different tumour types, and that the
mechanism of inhibition is through inhibiting angiogenesis rather
than a direct effect on tumour cell growth.
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